Clinical trials: Insulin Dependent Diabetes
Obesity &Amp; Overweight, Hypertension
A Prospective Randomnised Controlled Trial Comparing Overall Patient Compliance in a Bariatric Surgical Pathway Using the Standard Versus a More Intensified and Interactive Version of the "Get Ready" Smartphone Application.
The aim of this study is to assess the impact of a newly intensified digital platform following bariatric surgery. This will be measured using several questionnaires.
- Conditions
- Obesity &Amp; Overweight, Hypertension, Obstructive Sleep Apnea (OSAS), Diabetes Mellitus ( Type 1 and Type 2)
- Trial name
- NCT07297342
- Testing
- GetReady application, Intensified GetReady application
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Sint Dimpna Ziekenhuis Geel
Diabetes Mellitus, Type 1
Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)
The main objective of the study is to determine whether fully closed-loop insulin delivery using ultra-rapid acting insulin lispro will improve glucose control compared to standard lispro under conditions mimicking missed meal…
- Trial name
- ACOLYTE (NCT05660941)
- Testing
- Lispro
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Manchester University NHS Foundation Trust
Type 1 Diabetes Mellitus
Physiologic Response to Glucagon at Varying Insulin Levels
The purpose of this research study is to test how different levels of insulin block the effect of glucagon. Insulin is a hormone that lowers blood glucose. Glucagon raises blood glucose.
- Trial name
- NCT01483651
- Testing
- Glucagon, Insulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Legacy Health System
Diabetes Mellitus, Type 1
Telemedicine Program in Type 1 Diabetes and CSII
Diabetes mellitus is a chronic disease of high socio-health relevance for their clinical and economic implications (risk of complications, disability ...) (healthcare costs).
- Trial name
- NCT02790645
- Testing
- Group 2a. Telemedicine program, Group 1a. Control, Group 1b.Telemedicine program
- Volunteers
- 51 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Dysautonomia in Children With Type 1 Diabetes, Healthy Volunteer
Dysautonomia in Children With Type 1 Diabetes
Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their…
- Trial name
- DYSDIAB (NCT07455994)
- Testing
- Neurocoach® and Sudoscan®
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Type 1 Diabetes
Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus
The purpose of this study is to establish the safety and efficacy of xenotransplantation of DIABECELL® in patients with established type 1 diabetes mellitus
- Trial name
- NCT01739829
- Testing
- DIABECELL (R)
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- Diatranz Otsuka Limited
Type I Diabetes
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based human insulin products (marketed in USA) in…
- Trial name
- NCT01308437
- Testing
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Where
- 25 sites in United States, India
- Volunteers
- 134 people
- Sponsor
- Wockhardt
Type 1 Diabetes
Sweetgoals for Type 1 Diabetes
The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes.
- Trial name
- NCT04646473
- Testing
- Coaching, Incentives, Sweetgoals app
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Trustees of Dartmouth College
Melanoma
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study.
- Trial name
- NCT04305054
- Testing
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab
- Where
- 60 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitis, Cognition
Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)
LO5 study: The investigators are inviting a new group of youth (ages 7-16) who have been recently diagnosed with type 1 diabetes and their non-diabetic siblings.
- Trial name
- LO5/HY5 (NCT00879203)
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 1
Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes
At present, there are no therapeutic agents that can minimize severe hypoglycemia (low blood sugar) and its effects on long-term brain function.
- Trial name
- NCT00592072
- Testing
- Medium chain fatty acid (Octanoic and Decanoic acid)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Type 1 Diabetes
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
The hormone glucose-dependent insulinotropic polypeptide (GIP) is naturally produced in the intestine during a meal and stimulates insulin secretion from the pancreas.
- Trial name
- GIPALANIN (NCT06881472)
- Testing
- Glucose-dependent Insulinotropic Polypeptide (GIP), alanine
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Asger Lund, MD
Type 1 Diabetes
Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy
Type 1 diabetes (T1D) is an autoimmune disease that usually occurs in children and reduces their pancreatic islet beta cells and thereby limits insulin production.
- Trial name
- NCT01996228
- Testing
- Stem Cell Educator
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Tobacco Consumption, Bronchiolitis
Impact of Pediatrician Intervention on the Smoking Habits of Parents of Sick Children
Reducing tobacco consumption is a major public health objective, with the prevalence of active smoking estimated in 2017 at 26.9% of the French population aged 18 to 25.
- Trial name
- MUCODIABTAB (NCT04437641)
- Testing
- Tobacco questionnaire
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Toulouse
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Diabetic Ketoacidosis
Association of Systemic Immune-inflammation Index and Severity of Diabetic Ketoacidosis in Type 1 Diabetes Mellitus
Diabetic ketoacidosis (DKA) is the most serious metabolic complication of type 1 diabetes mellitus (T1DM). Insulin deficiency and inflammation play a role in the pathogenesis of DKA.
- Trial name
- NCT06251895
- Testing
- DKA protocol
- Where
- Kuwait
- Volunteers
- 241 people
- Sponsor
- Jahra Hospital
Type 1 Diabetes
Effects of Metreleptin in Type 1 Diabetes Mellitus
This study will add leptin therapy to the current insulin therapy of Type 1 Diabetics with the aim of lowering the total insulin requirements and suppressing the steep fluctuations typically associated with Type 1 Diabetes.
- Trial name
- NCT01268644
- Testing
- Leptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 1
Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation
This is a Phase II open, randomized, active comparator-controlled multi center study in patients with severe type-1 diabetes. This is a two-armed study where patients are randomized in a 2:1 ratio between IBsolvMIR and heparin.
- Trial name
- NCT03867851
- Testing
- IBsolvMIR, Heparin
- Where
- 5 sites in Netherlands, Norway and 1 more
- Volunteers
- 7 people
- Sponsor
- TikoMed AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.